All Interventions

    NMN (Nicotinamide Mononucleotide)

    Supplements
    NAD+ Precursors

    Direct precursor to NAD+ that may restore age-related NAD+ decline and support metabolic health and longevity.

    Evidence Summary

    7
    / 10Score
    Moderate
    Moderate Evidence

    Strong preclinical evidence. Human trials show improved insulin sensitivity and muscle function. Long-term outcomes still being studied. David Sinclair research widely cited. UPDATE (August 2026): A Nature Aging 2026 meta-analysis of more than 15,000 human DNA methylation profiles across 17 tissues (Jacques et al., with Horvath, Gladyshev and Teschendorff) used network analysis to separate tightly connected age-associated gene clusters that beneficial interventions do NOT move from a more modifiable cluster linked to NAD+ metabolism - the authors frame this as supporting NAD+ as a candidate therapeutic node in aging. This is meaningful as network-level evidence that NAD+ metabolism sits in an addressable part of the aging epigenome. It is NOT evidence that NMN or any NAD+ precursor supplement improves human aging outcomes; the analysis is cross-sectional and descriptive, with no supplementation arm. Separately, a peer-reviewed systematic review of 27 human nutrition trials (Ageing Research Reviews 2026) found that dietary supplement evidence for moving cellular-senescence biomarkers remains limited and heterogeneous. UPDATE (August 9, 2026): Two peer-reviewed papers this cycle bear on the sirtuin/NAD rationale, and both cut against over-reading it. (1) Nature Aging 2026 (Mu, Barthez et al.; D. Chen, Netea and Verdin labs) shows the mitochondrial deacetylase SIRT3 — highly expressed in hematopoietic stem cells and lost with age — suppresses an HSC response to aging that installs maladaptive trained immunity in myeloid progeny; HSC-specific SIRT3 overexpression improved HSC function and attenuated age-related declines in cognition and motility in distant tissues. This is a genuinely important relocation of inflammaging upstream to a trained stem-cell compartment, but SIRT3 was raised by transgenic overexpression in mice. There is no demonstration that NMN, NR or any NAD+ precursor raises HSC SIRT3 activity or reproduces any part of this phenotype. (2) Nature Aging 2026 (Cole, Buj et al.) identifies fructose as a metabolic component of the chemotherapy-induced SASP that drives ovarian-cancer cell detachment and metastatic dissemination specifically through inhibition of an NAD-SIRT-SREBP axis. That places NAD-sirtuin signalling inside a pro-dissemination pathway in an oncology context — preclinical and model-specific, but a reason for caution rather than confidence about NAD+ loading in patients with active or recent malignancy. UPDATE (September 20, 2026): A peer-reviewed measurement result that directly affects how NMN response is monitored. Nature Metabolism 2026;8:1282-1290 (Tretowicz, Schomakers et al.; Houtkooper lab, Amsterdam UMC) quantified NAD+ across seven independent human cohorts with a rigorously validated UHPLC-high-resolution MS method designed to account for real-world analytical variability, and found whole-blood NAD+ STABLE with chronological age and UNCHANGED by lifestyle interventions - while responding as expected to nicotinamide riboside supplementation. The authors conclude that blood NAD+ is not a useful biomarker of ageing or lifestyle, and that much of the previously reported age-related decline is plausibly assay variability. Scope this carefully: the paper does not refute tissue or intracellular NAD+ decline, does not test NMN specifically, and does not evaluate any clinical outcome of precursor supplementation - the mechanistic NAD+ rationale summarised above is untouched. What it does remove is the common practice of using a blood NAD+ level as a biological-age readout or as proof that a precursor is working; a supplement-induced rise demonstrates absorption, not benefit. Balancing this, GeroScience 2026 (Itabashi Longitudinal Study on Aging, 16 Sept 2026) reported that among 529 community-dwelling Japanese adults aged 65+, the 32 (6.0%) meeting revised J-CHS frailty criteria had lower median whole-blood NAD+ than non-frail participants, robust to adjustment for age, sex and fasting time and to spline, Firth penalised-likelihood and haematological sensitivity analyses. This is the clearest human association to date between circulating NAD+ and a functional outcome, and it is a legitimate reason to keep the axis under study - but it is cross-sectional with only 32 frail participants, reverse causation is unaddressed, and it tests no supplement. Human NMN evidence remains limited to short-duration surrogate endpoints. UPDATE (November 14, 2026): New clinical-outcome meta-analyses sharpen the human picture, and both are modest. (1) A 2026 systematic review and meta-analysis in Nutrients (Zhang M et al.; 10 RCTs, 349 participants with elevated blood pressure) found oral NMN associated with a small but statistically significant reduction in resting diastolic blood pressure versus placebo (weighted mean difference -2.15 mmHg, 95% CI -3.68 to -0.61); the pooled effect on systolic blood pressure was not significant overall but reached significance in adults aged 60 and older (-3.94 mmHg, 95% CI -7.06 to -0.82). (2) A separate 2026 Nutrients safety meta-analysis (Yang W et al.; 15 trials, doses 250-2000 mg/day for 14 days to 24 weeks) found NMN well tolerated, with no increase in overall, serious, or system-specific adverse events and no elevation of ALT or AST; it found no significant effect on body weight, BMI, fasting glucose, HbA1c, or lipids, with only a slight diastolic blood pressure reduction and a non-significant downward trend in HOMA-IR. (3) A 2024 post-hoc dose-response analysis (Kuerec/Maier et al., Mechanisms of Ageing and Development) of the 80-person 300/600/900 mg trial confirmed a dose-dependent rise in blood NAD+ that correlated with 6-minute-walk and SF-36 gains, but with very high between-person variability. Net: short-term oral NMN appears safe and may modestly lower blood pressure - most clearly diastolic, and systolic mainly in older adults - but broad metabolic benefits are not established and all endpoints remain short-duration surrogates. This is not a treatment for hypertension or any disease.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Converted to NAD+ via NMN adenylyltransferases. Supports sirtuin activation, DNA repair (PARP), mitochondrial function, and cellular energy metabolism.

    Who Is This For?

    Age-related decline, metabolic dysfunction, longevity optimization. NAD+ levels decrease significantly with age.

    Protocol & Dosing

    Dose

    250-1000mg daily. Common: 500mg morning.

    Frequency

    Daily

    Duration

    Ongoing

    Protocol Summary

    Oral supplementation, typically morning. Sublingual may improve absorption. Consider with TMG for methyl group support.

    Latest Evidence

    2026: new RCT meta-analyses on oral NMN

    Two 2026 meta-analyses in Nutrients now summarise the human trial evidence. Across 10 randomized controlled trials in 349 adults with elevated blood pressure, oral NMN was associated with a small but statistically significant drop in resting diastolic blood pressure versus placebo (-2.15 mmHg, 95% CI -3.68 to -0.61); the effect on systolic blood pressure was not significant overall but reached significance in adults aged 60 and older (-3.94 mmHg, 95% CI -7.06 to -0.82). A companion safety meta-analysis of 15 trials (250-2000 mg/day, 2-24 weeks) found NMN well tolerated, with no increase in serious adverse events and no rise in liver enzymes, but no meaningful change in weight, glucose, HbA1c, or lipids. An earlier dose-response analysis confirmed a dose-dependent rise in blood NAD+ that tracked with 6-minute-walk and quality-of-life gains, albeit with wide person-to-person variability.

    These are modest, short-duration surrogate endpoints, not evidence that NMN treats hypertension or any disease, and broad metabolic benefit has not been established. As noted in the record, a blood NAD+ rise reflects absorption rather than proven benefit. Discuss supplementation with your physician, particularly if you have a history of cancer or take other medications. Educational information, not medical advice.

    Pooled RCTs · n=349 · 2026 meta-analysis

    Modest blood-pressure reduction with oral NMN

    Source: Effects of nicotinamide mononucleotide supplementation on blood pressure - a systematic review and meta-analysis of randomized controlled trials, Nutrients 2026 (Zhang M et al.; 10 RCTs, 349 adults with elevated blood pressure). Bars show the pooled mean difference vs. placebo; 95% confidence intervals appear on hover. Pooled systolic BP across all adults was not statistically significant - the systolic effect shown is the prespecified subgroup aged 60 and older. These are modest, short-term surrogate findings and not a treatment for hypertension.

    Key references: NMN & blood pressure: systematic review & meta-analysis of RCTs - Nutrients (2026) · Safety & metabolism-related outcomes of oral NMN: meta-analysis - Nutrients (2026) · Dose-response NMN & NAD concentration - Mech. Ageing Dev. (2024)

    Interactions & Precautions

    Contraindications

    • None established

    Potential Risks

    • •Limited long-term human data
    • •Quality control concerns

    Potential Side Effects

    Mild GI upset (rare)
    Flushing (rare)

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Combine with TMG (betaine) to support methylation. Morning dosing preferred. Consider NAD+ testing to track. Quality varies significantly between brands. Updated August 2026: The 2026 cross-tissue methylation atlas gives a defensible mechanistic rationale for interest in NAD+ metabolism, and patients will cite it. Be precise about what it does and does not show - it identifies NAD+-linked methylation as a modifiable module in a network analysis; it does not test supplementation and reports no clinical outcome. Human NMN trial evidence remains limited to short-duration surrogate endpoints. Continue to set expectations accordingly rather than upgrading the recommendation on the strength of this paper. Updated August 9, 2026: Expect patients to cite the 2026 SIRT3 stem-cell paper as support for NAD+ precursors. It is not. SIRT3 was manipulated genetically in mice; no supplement has been shown to raise HSC SIRT3 activity. Separately, the 2026 SASP-fructose work situates the NAD-SIRT-SREBP axis inside a pathway promoting metastatic dissemination in chemotherapy-treated ovarian cancer models — preclinical, but enough to warrant a conservative stance on NAD+ loading in patients with active malignancy or on recent cytotoxic therapy, and to prompt an explicit oncology-history question before starting. Human NMN evidence remains short-duration surrogate endpoints. Updated September 20, 2026: A specific change to monitoring practice. The prior note here recommended considering NAD+ testing to track response - that recommendation should now be withdrawn. Nature Metabolism 2026 (seven human cohorts, validated UHPLC-HRMS) found whole-blood NAD+ does not decline with age and does not move with lifestyle, moving only with precursor supplementation. So a blood NAD+ level cannot serve as a biological-age readout, cannot establish that a patient "needs" NMN, and a post-supplement rise confirms absorption rather than benefit. If tracking is wanted, use functional and clinical endpoints, not a blood NAD+ number. Two further points for consultation: (1) patients who have purchased consumer NAD+ testing should be told plainly that the assay has not been validated as an aging biomarker and that reported age-related declines may largely reflect analytical variability; (2) the GeroScience 2026 frailty association (lower whole-blood NAD+ in the 6% who were frail, n=529) will be cited as a counterargument - it is real and worth knowing, but it is cross-sectional, reverse causation is untested, and it studied no supplement. Continue to combine with TMG for methylation support, prefer morning dosing, and keep expectations anchored to short-duration surrogate-endpoint evidence. Updated November 14, 2026: Two 2026 meta-analyses now bound the near-term clinical expectation. Tolerability looks good across 250-2000 mg/day with no signal of liver-enzyme or serious adverse-event elevation, which supports a conservative trial in motivated patients. Efficacy is modest and mostly vascular: roughly a 2 mmHg diastolic reduction overall and roughly a 4 mmHg systolic reduction in adults 60+, with no reliable effect on weight, glucose, HbA1c or lipids. Frame NMN as a low-risk, modest-signal adjunct - not a blood-pressure therapy and not a substitute for established cardiovascular and metabolic care. Continue to anchor expectations to short-duration surrogate endpoints, keep the morning-dosing and TMG guidance, and (per the September note) do not rely on blood NAD+ levels to confirm benefit. Educational information, not medical advice.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $$

    Accessibility

    OTC supplement

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation